Research on new drugs to block endothelin has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. Whether the new drugs can treat ...

This is a developing news story. Please check back soon for updates. The FDA granted full approval to sparsentan for ...

Sparsentan received full FDA approval for FSGS in patients aged 8–75 years, addressing a rare, progressive glomerulopathy ...

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

The potent vasoconstrictor peptide endothelin-1 (ET-1) was first isolated from the culture media of porcine endothelial cells in 1988 (Yanagisawa et al, 1988). It is one of a family of multifunctional ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

The ASCEND study was a large, international trial that aimed to assess the effects of avosentan on diabetic nephropathy. To the disappointment of the nephrology community who had anticipated that the ...

The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...

LONG BEACH, Calif. -- Two different ocular implants eluting an endothelin antagonist showed early promise for slowing diabetic eye disease, according to two small studies reported here. In a ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well ...

According to the FDA, the labeling alone should be adequate to communicate the risk of embryofetal toxicity. The Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation ...

Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors PATIENTS AND METHODS: Patients who were 18 years or older and ...